Table 4.

Biologic data for patients with diabetes

QUALITY INDICATORBASELINE, N/N (%)*6-MO FOLLOW-UP, N/N (%)*12-MO FOLLOW-UP, N/N (%)*18-MO FOLLOW-UP, N/N (%)*24-MO FOLLOW-UP, N/N (%)*P VALUE
HbA1c≤ 7%73/136 (54)67/111 (60)69/106 (65)78/109 (72)62/84 (74).0003
LDL ≤ 2.0 mmol/L57/112 (51)44/82 (54)45/89 (51)55/85 (65)41/72 (57).15
Test for microalbuminuria done in past 6 mo or ordered at the visit44/145 (30)49/142 (35)52/130 (40)54/126 (43)47/102 (46).003
BP < 130/80 mm Hg in patients for whom microalbuminuria was absent (ACR < 2.0 mg/mmol in men or < 2.8 mg/mmol in women) or unreported21/69 (30) (microalbuminuria absent or unreported, N = 107)26/80 (33) (microalbuminuria absent or unreported, N = 111)30/83 (36) (microalbuminuria absent or unreported, N = 105)33/84 (39) (microalbuminuria absent or unreported, N = 93)20/55 (36) (microalbuminuria absent or unreported, N = 71).27
BP < 125/75 mm Hg in patients for whom microalbuminuria was present4/30 (13) (microalbuminuria present, N = 38)5/24 (21) (microalbuminuria present, N = 31)5/21 (24) (microalbuminuria present, N = 25)8/32 (25) (microalbuminuria present, N = 33)6/29 (21) (microalbuminuria present, N = 31).4
Currently taking ASA or ASA use was recommended at the visit114/145 (79)104/142 (73)89/130 (68)86/126 (68)68/102 (67).019
Currently taking an ACEI or ARB, or ACEI or ARB use was recommended, in patients with BP ≥ 130 mm Hg or where microalbuminuria was present68/86 (79)68/85 (80)64/78 (82)59/84 (70)47/66 (71).09
  • ACEI—angiotensin-converting enzyme inhibitor, ACR—albumin-creatinine ratio, ARB—angiotensin receptor blocker, ASA—acetylsalicylic acid, BP—blood pressure, HbA1c—hemoglobin A1c, LDL—low-density lipoprotein.

  • * Of the participants initially recruited, data were available for all 145 participants at baseline, 142 participants at 6 mo, 130 participants at 12 mo, 126 participants at 18 mo, and 102 participants at 24 mo. Some patients had no data available, some died during the study, and some stopped attending the practice.

  • Denominators reflect the number of patients for whom both measures were available.